Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avid Radiopharmaceuticals Inc.

Division of Eli Lilly & Co.
www.avidrp.com

Latest From Avid Radiopharmaceuticals Inc.

Neuro Medtech Investors Have Time (And Money) For The Pain

START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.

Medical Device

Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments

Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.

BioPharmaceutical Deals

FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns

Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.

BioPharmaceutical Medical Device

Piramal Alzheimer's imaging agent gets EU thumbs up

The EU's CHMP has granted a positive opinion to marketing for another imaging agent for use in Alzheimer's disease, Piramal Imaging's NeuraCeq (florbetaben). It gave the go-ahead for Lilly and Avid Radiopharmaceuticals' Amyvid (florbetapir F 18 injection), the first Alzheimer's imaging agent to reach the market, in October 2012 (scripintelligence.com, 24 October 2012). GE Healthcare's similar product Vizamyl (18F flutemetamol) recently received US approval (scripintelligence.com, 30 October 2013).

Neurology Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Daniel Skovronsky, MD, PhD, CEO
    Michael J Pontecorvo, PhD, VP, Clin. Dev.
    Mark A Mintun, MD, CMO
  • Contact Info
  • Avid Radiopharmaceuticals Inc.
    Phone: (215) 298-0700
    3711 Market St., 7th Fl.
    Philadelphia, PA 19104
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register